Table 5 Comparison between hMICL expression and AML patients’ data
Parameters | Variables | HMICL (N = 63) | P value | |
|---|---|---|---|---|
Negative (N = 8) | Positive (N = 55) | |||
Gender: | Male | 4 (50%) | 23 (41.8%) | 0.473 |
Female | 4 (50%) | 32 (58.2%) | ||
Liver | Normal | 6 (75 %) | 38 (69.1%) | 0.545 |
Enlarged | 2 (25%) | 17 (30.1%) | ||
Spleen | Normal | 4 (50%) | 36 (65.5%) | 0.0318 |
Enlarged | 4 (50%) | 19 (34.6%) | ||
Lymph node | Normal | 5 (62.5%) | 39 (70.9 %) | 0.455 |
Enlarged | 3 (37.5%) | 16 (29.1%) | ||
Response (28 days) | Died | 0 (0%) | 17 (30.9%) | 0.001 |
CR | 8 (100%) | 12 (21.8%) | ||
PR | 0 (0%) | 26 (47.3%) | ||
Response (6 months) | Died | 0 (0%) | 26 (47.3%) | 0.001 |
CR | 8 (100%) | 11 (20.0%) | ||
PR | 0 (0%) | 18 (32.7%) | ||
Response (24 months) | Died or relapse | 0 (%) | 37 (67.3%) | 0.001 |
CR | 8 (100%) | 18 (32.7%) | ||
AML subtype | M0 | 1 (12.5%) | 3 (5.5%) | 0.138 |
M1 | 2 (25%) | 12 (21.8%) | ||
M2 | 3 (37.5%) | 24 (43.6%) | ||
M4 | 0 (0%) | 3 (5.5%) | ||
M5 | 1 (12.5%) | 13 (23.6%) | ||
M7 | 1 (12.5%) | 0 (0%) | ||
Immunophenotyping | CD33- | 1 (12.5%) | 4 (7.3%) | 0.505 |
CD33+ | 7 (87.2%) | 51 (92.7%) | ||
CD13- | 2 (25%) | 7 (12.7%) | 0.320 | |
CD13+ | 6 (75%) | 48 (87.3%) | ||
CD14- | 6 (75%) | 50 (90.9%) | 0.214 | |
CD14+ | 2 (25%) | 5 (9.1%) | ||
CD117- | 2 (25%) | 17 (30.9%) | 0.545 | |
CD117+ | 6 (75%) | 38 (69.1%) | ||
MPO- | 3(37.5%) | 7 (12.7%) | 0.106 | |
MPO+ | 5 (62.5%) | 48 (87.3%) | ||
CD34- | 4 (50%) | 22 (40%) | 0.433 | |
CD34+ | 4 (50%) | 33 (60%) | ||